Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 3/20 | 0.36 |
| ▸ | MME | P08473 | 2/20 | 0.35 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.34 |
| ▸ | ITGAL | P20701 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29630501 | 0.96 | BACE1 (0.34) | ECE1MMEPDCD1LG2CD274BACE1 | |
| SCHEMBL29851664 | 0.95 | MME (0.38) | ECE1MMEITGB2ICAM1ITGAL | |
| SCHEMBL29373629 | 0.94 | ECE1 (0.39) | ECE1MMEITGB2ICAM1ITGAL | |
| SCHEMBL30209180 | 0.94 | PDCD1LG2 (0.36) | ECE1MMEITGB2ICAM1ITGAL | |
| SCHEMBL30038078 | 0.92 | MME (0.39) | ECE1MMECA2CA1 | |
| SCHEMBL31707374 | 0.91 | MME (0.38) | ECE1MMEITGB2ICAM1ITGAL | |
| SCHEMBL29447737 | 0.91 | MME (0.36) | ECE1MMEBACE1 | |
| SCHEMBL30192164 | 0.91 | BACE1 (0.36) | ECE1MMEITGB2ICAM1ITGAL | |
| SCHEMBL29560167 | 0.91 | MME (0.36) | MME | |
| SCHEMBL29376470 | 0.90 | MME (0.36) | MMEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144860-A1 | HIV-1 ENV FUSION PEPTIDE IMMUNOGENS AND THEIR USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2026-05-28 | — | — | US | disclosed |
| US-12458691-B2 | HIV-1 ENV fusion peptide immunogens and their use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-11-04 | — | — | US | disclosed |
| US-20230338507-A1 | HIV-1 ENV FUSION PEPTIDE IMMUNOGENS AND THEIR USE | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-10-26 | — | — | US | disclosed |
| US-11602559-B2 | HIV-1 Env fusion peptide immunogens and their use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-03-14 | — | — | US | disclosed |
| EP-4070815-A1 | HIV-1 ENV FUSION PEPTIDE IMMUNOGENS AND THEIR USE | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2022-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338507-A1 | HIV-1 ENV FUSION PEPTIDE IMMUNOGENS AND THEIR USE | CD4, LY96, ICOS | ECE1 194/4885MME 92/4885ITGB2 4067/4885 |
| US-20260144860-A1 | HIV-1 ENV FUSION PEPTIDE IMMUNOGENS AND THEIR USE | CD4, TIMCC, CD81 | ECE1 2749/4885MME 3828/4885ITGB2 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.